lotiglipron

Lotiglipron is an oral, small-molecule, non-peptide glucagon-like peptide-1 receptor (GLP-1R) agonist developed by Pfizer for the treatment of type 2 diabetes and obesity. It was designed to mimic the effects of endogenous GLP-1, stimulating insulin secretion in response to meals, inhibiting glucagon secretion to reduce hepatic glucose output, slowing gastric emptying to promote satiety and weight loss, and ultimately lowering blood sugar levels. Lotiglipron demonstrated dose-dependent reductions in glycated hemoglobin (HbA1c) and body weight in clinical trials. However, its development was terminated after early-stage studies revealed elevated liver enzymes indicative of potential liver toxicity[1][2][5][6][7].